Scholar Rock (SRRK) Scheduled to Post Earnings on Tuesday

Scholar Rock (NASDAQ:SRRK - Get Free Report) is scheduled to be announcing its earnings results before the market opens on Tuesday, November 12th. Analysts expect the company to announce earnings of ($0.60) per share for the quarter. Parties that wish to register for the company's conference call can do so using this link.

Scholar Rock (NASDAQ:SRRK - Get Free Report) last posted its earnings results on Thursday, August 8th. The company reported ($0.60) earnings per share for the quarter, beating analysts' consensus estimates of ($0.61) by $0.01. During the same period in the previous year, the business posted ($0.47) EPS. On average, analysts expect Scholar Rock to post $-2 EPS for the current fiscal year and $-2 EPS for the next fiscal year.

Scholar Rock Price Performance

Scholar Rock stock traded up $0.96 during mid-day trading on Tuesday, hitting $28.63. 677,110 shares of the company traded hands, compared to its average volume of 1,140,798. The stock has a fifty day moving average price of $17.17 and a 200-day moving average price of $12.73. Scholar Rock has a one year low of $6.76 and a one year high of $35.38. The company has a debt-to-equity ratio of 0.36, a quick ratio of 6.04 and a current ratio of 6.04. The stock has a market cap of $2.29 billion, a price-to-earnings ratio of -12.90 and a beta of 0.47.

Wall Street Analyst Weigh In

A number of analysts have recently weighed in on SRRK shares. HC Wainwright increased their price objective on Scholar Rock from $30.00 to $35.00 and gave the company a "buy" rating in a research note on Monday, October 7th. BMO Capital Markets upped their price target on Scholar Rock from $34.00 to $38.00 and gave the stock an "outperform" rating in a research note on Friday, October 11th. Wedbush reaffirmed an "outperform" rating and set a $37.00 price objective on shares of Scholar Rock in a research report on Monday. Piper Sandler increased their price target on Scholar Rock from $28.00 to $42.00 and gave the company an "overweight" rating in a report on Tuesday, October 15th. Finally, JPMorgan Chase & Co. boosted their target price on shares of Scholar Rock from $18.00 to $31.00 and gave the company an "overweight" rating in a research report on Monday, October 14th. Six research analysts have rated the stock with a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat, Scholar Rock currently has an average rating of "Buy" and an average target price of $33.29.

Insider Activity at Scholar Rock

In other Scholar Rock news, CFO Edward H. Myles sold 206,240 shares of Scholar Rock stock in a transaction dated Monday, October 7th. The stock was sold at an average price of $26.56, for a total transaction of $5,477,734.40. Following the completion of the sale, the chief financial officer now owns 161,088 shares of the company's stock, valued at approximately $4,278,497.28. The trade was a 0.00 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. In other news, insider Tracey Sacco sold 30,000 shares of the business's stock in a transaction dated Monday, October 7th. The stock was sold at an average price of $25.62, for a total value of $768,600.00. Following the completion of the transaction, the insider now owns 49,285 shares of the company's stock, valued at $1,262,681.70. The trade was a 0.00 % decrease in their position. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Also, CFO Edward H. Myles sold 206,240 shares of the firm's stock in a transaction dated Monday, October 7th. The stock was sold at an average price of $26.56, for a total value of $5,477,734.40. Following the sale, the chief financial officer now directly owns 161,088 shares in the company, valued at approximately $4,278,497.28. This trade represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 1,415,340 shares of company stock valued at $40,666,088 in the last three months. 19.20% of the stock is owned by insiders.

Scholar Rock Company Profile

Scholar Rock Holding Corporation, a biopharmaceutical company, focuses on the discovery, development, and delivery of medicines for the treatment of serious diseases in which signaling by protein growth factors plays a fundamental role. The company develops Apitegromab, an inhibitor of the activation of myostatin that is in Phase 3 clinical trial for the treatment of spinal muscular atrophy; and SRK-181, which has completed Phase 1 clinical trials for the treatment of cancers that are resistant to checkpoint inhibitor therapies, such as anti-PD-1 or anti-PD-L1 antibody therapies.